Spinal Muscular Atrophy Type I: Is It Ethical to Standardize Supportive Care Intervention in Clinical Trials?

Por Finkel, Richard S., Bishop, Kathie M., Nelson, Robert M.
Publicado no J Child Neurol (2016)

Therapeutic potential of CERE-110 (AAV2-NGF): Targeted, stable, and sustained NGF delivery and trophic activity on rodent basal forebrain cholinergic neurons

Por Bishop, Kathie M., Hofer, Eva K., Mehta, Arpesh, Ramirez, Anthony, Sun, Liangwu, Tuszynski, Mark, Bartus, Raymond T.
Publicado em 2008

Intrathecal Injections in Children With Spinal Muscular Atrophy: Nusinersen Clinical Trial Experience

Por Haché, Manon, Swoboda, Kathryn J., Sethna, Navil, Farrow-Gillespie, Alan, Khandji, Alexander, Xia, Shuting, Bishop, Kathie M.
Publicado no J Child Neurol (2016)

Intraparenchymal spinal cord delivery of adeno-associated virus IGF-1 is protective in the SOD1(G93A) model of ALS

Por Lepore, Angelo C., Haenggeli, Christine, Gasmi, Mehdi, Bishop, Kathie M., Bartus, Raymond T., Maragakis, Nicholas J., Rothstein, Jeffrey D.
Publicado em 2007

Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy

Por Chiriboga, Claudia A., Swoboda, Kathryn J., Darras, Basil T., Iannaccone, Susan T., Montes, Jacqueline, De Vivo, Darryl C., Norris, Daniel A., Bennett, C. Frank, Bishop, Kathie M.
Publicado no Neurology (2016)